Market Overview:
Cell therapy is a type of immunotherapy that helps boost the body’s natural defenses to fight disease. Cell therapy manufacturing involves the development and large-scale production of tumor-infiltrating lymphocytes, natural killer cells, macrophages, and other cells that can treat cancer and various other chronic diseases. Emerging cell therapy approaches like chimeric antigen receptor T-cell therapy are gaining popularity for treating cancer and other difficult-to-cure diseases.
Market key trends:
One of the major trends in the cell therapy manufacturing market is the rising focus on automation. Fully automated cell therapy manufacturing processes help improve the reproducibility, scalability, and control over cell production. Technologies like closed single-use bioreactors, culture bags, and automated cell processing units have enabled the development of standardized and closed manufacturing platforms. This assists in overcoming challenges related to aseptic operation, cell contamination, and manual handling. Automation helps enhance cell therapy manufacturing efficiency and supports meeting the growing demand.
Porter’s Analysis
Threat of new entrants: The cell therapy manufacturing market requires high capital investments for setting up facilities. Regulatory compliances also make the entry barriers high for new players.
Bargaining power of buyers: As the cell therapy manufacturing services are highly specialized, buyers have limited alternatives and thus the bargaining power of buyers is low.
Bargaining power of suppliers: Due to the technological expertise required, the bargaining power of suppliers of critical raw materials and instruments is high.
Threat of new substitutes: There are limited substitutes available for cell therapy. Other therapies like gene therapy pose a limited threat currently.
Competitive rivalry: The market is highly competitive with presence of few global players. Companies compete based on technical expertise, portfolio, and pricing.
The global Cell Therapy Manufacturing Market Size is estimated to be valued at US$ 12.99 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Key Takeaways
The global Cell Therapy Manufacturing Market is expected to witness high growth, exhibiting a CAGR of 15% over the forecast period, due to the increasing prevalence of chronic diseases and growing demand for effective treatment options.
Regional analysis: North America is expected to dominate the cell therapy manufacturing market owing to rapid adoption of new technologies and the presence of major market players in the US. Asia Pacific is anticipated to exhibit the highest growth rate due to rapidly growing biotechnology industry and increasing government support for cell-based research in countries like China and India.
Key players: Key players operating in the cell therapy manufacturing market are WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HELIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc. These players are focusing on scalable and customizable manufacturing solutions to cater to rising client demand.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
